Multicentre , double-blind , sequential-cohort , randomised controlled trial with laquinimod doses of 0.5 , 1 , 1.5 or 2mg/day or placebo ( n = 45 per cohort randomised in a 2:1 ratio ) for 8weeks with 4-week follow-up .